Verici Dx (Verici Dx) Retained Earnings : $-29.75 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Verici Dx's retained earnings for the quarter that ended in Jun. 2023 was $-29.75 Mil.

Verici Dx's quarterly retained earnings declined from Jun. 2022 ($-18.53 Mil) to Dec. 2022 ($-24.47 Mil) and declined from Dec. 2022 ($-24.47 Mil) to Jun. 2023 ($-29.75 Mil).

Verici Dx's annual retained earnings declined from Dec. 2020 ($-4.74 Mil) to Dec. 2021 ($-13.07 Mil) and declined from Dec. 2021 ($-13.07 Mil) to Dec. 2022 ($-24.47 Mil).

Verici Dx Retained Earnings Historical Data

The historical data trend for Verici Dx's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Retained Earnings Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Retained Earnings

-4.74

-13.07

-24.47

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Retained Earnings	-7.57	-13.07	-18.53	-24.47	-29.75

Verici Dx Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Verici Dx (OTCPK:VRCDF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines